Vasopressin Antagonists for the Treatment of Acute Decompensated Heart Failure: When, for Whom, for How Long, and on What Standard Therapy?

Journal of Cardiac Failure

Volumn 14, Issue 8, 2008, Pages 648-650

  Filippatos, Gerasimos ^a   Parissis, John T ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; CONIVAPTAN; LIXIVAPTAN; MOZAVAPTAN; RELCOVAPTAN; RWJ 351647; RWJ 676070; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

ADRENAL HYPERPLASIA; ANXIETY DISORDER; BRAIN EDEMA; BRAIN VASOSPASM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CUSHING SYNDROME; DEPRESSION; DIABETIC NEPHROPATHY; DYSMENORRHEA; DYSPNEA; EDITORIAL; GLAUCOMA; HEART FAILURE; HUMAN; HYPERVOLEMIA; HYPONATREMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; OAT CELL CARCINOMA; PERIPHERAL EDEMA; PREMATURE LABOR; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

ACUTE DISEASE; BENZAZEPINES; DIURESIS; HEART FAILURE; HUMANS; RECEPTORS, VASOPRESSIN; VASOPRESSINS;

EID: 52949089955     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.08.003     Document Type: Editorial

References (23)

1. Alla F., Zannad F., and Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 12 (2007) 91-95
2. Filippatos G., and Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev 12 (2007) 87-90
3. Gheorghiade M., Zannad F., and Sopko G. et al, for the International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
4. Gheorghiade M., Filippatos G., De Luca L., and Burnett Jr. J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 119 12 Suppl 1 (2006) S3-S10
5. Decaux G., Soupart A., and Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371 (2008) 1624-1632
6. Goldsmith S.R., and Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 46 (2005) 1785-1791
7. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O'Connor C.M., Gheorghiade M., et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
8. Tahara A., Tsukada J., Tomura Y., Suzuki T., Yatsu T., and Shibasaki M. Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol 35 (2008) 586-593
9. Goldsmith S.R. Vasopressin: a therapeutic target in congestive heart failure?. J Card Fail 5 (1999) 347-356
10. Clair M.J., King M.K., Goldberg A.T., et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 293 (2000) 852-860
11. De Luca L., Mebazaa A., Filippatos G., Parissis J.T., Böhm M., Voors A.A., et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail 10 (2008) 201-213
12. Abraham W., Shamshirsaz A.A., McFann K., Oren R.M., and Schrier R.W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47 (2006) 1615-1621
13. Gheorghiade M., Gattis W.A., O'Connor C.M., Adams Jr. K.F., Elkayam U., Barbagelata A., et al. for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
14. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
15. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
16. Gheorghiade M., Niazi I., and Ouyang J. et al, for the tolvaptan Investigators. Vasopressin V2-receptor blockade with Tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
17. Udelson J.E., McGrew F.A., Flores E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral Tolvaptan on left ventricular dilation and function in patient with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
18. Wada K., Fujimori A., Matsukawa U., Arai Y., Sudoh K., Yatsu T., et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 507 (2005) 145-151
19. Udelson J.E., Smith W.B., Hendrix G.H., Painchaud C.A., Ghazzi M., Thomas I., et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
20. Goldsmith S., Elkayam U., Haught H., Barve A., and He W. Efficacy and safety of V1A/V2-recepto Antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 14 (2008) 641-647
21. Bolignano D., Coppolino G., Criseo M., Campo S., Romeo A., and Buemi M. Aquaretic agents: what's beyond the treatment of hyponatremia?. Curr Pharm Des 13 (2007) 865-871
22. Filippatos G., Rossi J., Lloyds-Jones D.M., et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 13 (2007) 360-364
23. Rossi J., Bayram M., Udelson J.E., et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care 9 (2007) 82-86